Derek

Investment Committee

Derek Brandt is the CEO of the DCB, a global center for diabetes technology innovation that transforms diagnosis and treatment and improves quality of life.  He has extensive senior executive experience in the biotech, medtech and pharma industries, most recently as CEO of Sensile Medical prior to its acquisition by Gerresheimer in 2018.

Cookies

This website is using necessary cookies to provide a good browsing experience, see our Cookie Policy. These include essential cookies that are necessary for the operation of the siteor for comfort settings.

Cookies

This website is using necessary cookies to provide a good browsing experience, see our Cookie Policy. These include essential cookies that are necessary for the operation of the siteor for comfort settings.

Your cookie preferences have been saved.